JP2014525939A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525939A5
JP2014525939A5 JP2014527142A JP2014527142A JP2014525939A5 JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5 JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5
Authority
JP
Japan
Prior art keywords
ifnλ1
complex
pharmaceutical composition
peg
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014527142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/027317 external-priority patent/WO2013028233A1/en
Publication of JP2014525939A publication Critical patent/JP2014525939A/ja
Publication of JP2014525939A5 publication Critical patent/JP2014525939A5/ja
Withdrawn legal-status Critical Current

Links

JP2014527142A 2011-08-25 2012-03-01 ペグインターフェロンλ1複合体 Withdrawn JP2014525939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
VNVN1-2011-02222 2011-08-25
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (2)

Publication Number Publication Date
JP2014525939A JP2014525939A (ja) 2014-10-02
JP2014525939A5 true JP2014525939A5 (enExample) 2015-04-09

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527142A Withdrawn JP2014525939A (ja) 2011-08-25 2012-03-01 ペグインターフェロンλ1複合体

Country Status (9)

Country Link
EP (1) EP2748328A4 (enExample)
JP (1) JP2014525939A (enExample)
CN (1) CN103228792A (enExample)
AU (1) AU2012299423A1 (enExample)
BR (1) BR112014004302A2 (enExample)
CA (1) CA2846092A1 (enExample)
RU (1) RU2014111179A (enExample)
WO (1) WO2013028233A1 (enExample)
ZA (1) ZA201401159B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3416675T (lt) 2016-02-19 2021-06-25 Eiger Biopharmaceuticals, Inc. Hepatito delta viruso infekcijos gydymas interferonu lambda
ES3015227T3 (en) 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
RU2678332C1 (ru) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
CN112245570A (zh) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
JP2024504341A (ja) 2021-01-21 2024-01-31 シャーメン アモイトップ バイオテック カンパニー, リミテッド 癌を治療するためのインターフェロンベースの方法及び組合せ医薬
CA3206005A1 (en) 2021-01-21 2022-07-28 Xiaojin Liao Method and pharmaceutical combination for preventing cancer recurrence
CN120676955A (zh) 2022-12-09 2025-09-19 Dys免疫治疗公司 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388B (zh) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 含有人干扰素的药物组合物
WO2006133088A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
DK1931704T3 (da) * 2005-10-04 2011-03-14 Zymogenetics L L C Frembringelse og rensning af IL-29
CN101002942B (zh) * 2007-01-08 2010-07-21 湖南大学 一种peg化脂质体纳米颗粒
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C

Similar Documents

Publication Publication Date Title
JP5578853B2 (ja) ウイルス感染の治療のための化合物、及び医薬組成物
JP2013507439A5 (enExample)
RU2014111179A (ru) КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ
JP2012513479A5 (enExample)
JP2021100937A5 (enExample)
JP2012521201A5 (enExample)
JP2011500814A5 (enExample)
JP2015512860A5 (enExample)
JP2013521279A5 (enExample)
JP2013537418A5 (enExample)
JP2016503800A5 (enExample)
JP2014515762A5 (enExample)
JP2013537905A5 (enExample)
JP2011529918A5 (enExample)
Lalani et al. Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease
RU2010106430A (ru) Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
RU2010126598A (ru) Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в
JP2018512428A5 (enExample)
JP2014515377A5 (enExample)
US20150202218A1 (en) Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
JP2008528624A5 (enExample)
Goh et al. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B
NZ583831A (en) Protein-polymer conjugates comprising interferon-alpha
JP2011521648A5 (enExample)